new-kit-box new-kit-box new-kit-box new-kit-box

ELISA Alternative for VEGF-A Detection

  • Cell-based assay with fast add-and-read protocol​
  • Luminescent detection with any plate-reading luminometer​
  • Scalable to 96- or 384- well plates, protocols included
  • Pack sizes show assay number for 96-well plates

Catalog Number:

Choose a product

Size

$ 665.00

Catalog Number: W1880

Add W1880 to Cart

$ 4,326.00

Catalog Number: W1881

Add W1881 to Cart

$ 2,487.00

Catalog Number: W1882

Add W1882 to Cart

$ 143.00

Catalog Number: W188A-C

Add W188A-C to Cart


to see your price

Solicitar una Muestra

Overview
Protocols
Specifications
Resources
Related Products

Quantify VEGF-A Release in Less Than 70 Minutes

The Lumit® VEGF-A Immunoassay quantitatively measures released VEGF-A in cell culture samples using a simple, no-wash protocol. Just add labeled antibodies to the sample, add detection reagent and read luminescent signal using a standard plate-reading luminometer—the entire protocol is completed in less than 70 minutes. Use the assay directly on cells in culture or culture medium transferred to a separate assay plate.

Note: The total number of assays per kit will vary based on final well volume.

For standard well volumes:

  • 100 assay kits: applicable for 100 assays in 96-well plates or 400 assays in 384-well plates.
  • 500 assay kits: applicable for 500 assays in 96-well plates or 2,000 assays in 384-well plates.
  • 1,000 assay kits: applicable for 1,000 assays in 96-well plates or 4,000 assays in 384-well plates.

How the Lumit® VEGF-A Immunoassay Works

Primary antibodies to VEGF-A were selected for their specific and sensitive detection and labeled with the LgBiT and SmBiT subunits of NanoBiT® Luciferase. In the presence of VEGF-A, the subunits come together to form an active luciferase enzyme. Addition of optimized substrate generates a bright luminescent signal proportional to VEGF-A levels. The assay recognizes human VEGF-A, but not mouse or rat VEGF-A. It is specific for VEGF-A (121, 165 and 183) and does not cross-react with VEGF-B, -C and -D family members.

Schematic showing Lumit® Immunoassay concept.

Avoid Tedious Wash Steps with Simple One-Plate Protocol

Lumit® Immunoassay Workflow

Broad Linear Range of Lumit® VEGF-A Detection

The picomolar to nanomolar linear detection range of the Lumit® VEGF-A Immunoassay covers expected concentrations for most cell models.

 

Graph showing standard curve for Lumit® VEGF-A (Human) Immunoassay.

Specification

Lumit® VEGF-A Immunoassay

Dynamic Range

17.3–7,500pg/ml

Limit of Detection

4.8pg/ml (3 SD above background)

Minimal Detectable Dose (MDD)

3.6pg/ml (2 SD above background)

Assay Time

70 minutes

Sample Type

Cell culture supernatants

SD=Standard Deviation

High-Throughput Screening Applications

Optimizing the Lumit® IL-6 Immunoassay for High-Throughput Drug Screening

In this webinar, we share key considerations for scaling Lumit® Immunoassays from a single 96-well plate to many 364-well plates and offer tips for optimizing Lumit® Immunoassays for HTS applications. You will also hear Galapagos scientist Dr. Nick Verstraeten share how his team used the Lumit® IL-6 Immunoassay in a screening campaign for antiviral drugs.

View On-Demand Webinar

Lumit® Cytokine Assay Automation for High-Throughput Screening

In this poster, see miniaturization and automation data for Lumit® cytokine assays.

View Poster

Reproducible Detection of VEGF-A Released from Human Epithelial Cells

Bar graph showing a dose-dependent increase in VEGF-A released from human A549 epithelial cells.

Human A549 epithelial cells (20,000/well) were cultured in 96-well plates, and medium was refreshed at different timepoints to track VEGF-A accumulation over two days. After incubation, the Lumit® VEGF-A Immunoassay was used to quantitate VEGF-A in the media.

 

Need to measure a different target?

View our growing portfolio of
Lumit® Immunoassays.

For a biotech that understands time is of significant value, the Lumit® Immunoassays are an essential way for us to gather reliable data fast so that we can reach conclusions and make decisions sooner.

Jonathan Chow, Principal Scientist, Corner Therapeutics

Specifications

Catalog Number:

Contenido

Item Part # Presentación

Lumit® Detection Substrate B

VB405A 1 × 160μl

Lumit® Detection Buffer B

VB406A 1 × 3.2ml

Anti-hVEGF-A mAb-SmBiT, 500X

W189A 1 × 30μl

Anti-hVEGF-A mAb-LgBiT, 500X

W190A 1 × 30μl

Human VEGF-A Standard

W188A 1 × 25μl

Certificado de Análisis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Condiciones de Almacenaje

AA

Patentes y Exclusiones

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,797,889, 9,797,890, 10,107,800 and 11,493,504; European Pat. No. 2970412; Japanese Pat. Nos. 7280842 and 7532562; and other patents and patents pending.

Contenido

Item Part # Presentación

Lumit® Detection Substrate B

VB405B 1 × 1.25ml

Lumit® Detection Buffer B

VB406B 1 × 25ml

Anti-hVEGF-A mAb-SmBiT, 500X

W189B 1 × 300μl

Anti-hVEGF-A mAb-LgBiT, 500X

W190B 1 × 300μl

Human VEGF-A Standard

W188A 1 × 25μl

Certificado de Análisis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Condiciones de Almacenaje

AA

Patentes y Exclusiones

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,797,889, 9,797,890, 10,107,800 and 11,493,504; European Pat. No. 2970412; Japanese Pat. Nos. 7280842 and 7532562; and other patents and patents pending.

Contenido

Item Part # Presentación

Lumit® Detection Substrate B

VB405A 5 × 160μl

Lumit® Detection Buffer B

VB406A 5 × 3.2ml

Anti-hVEGF-A mAb-SmBiT, 500X

W189A 5 × 30μl

Anti-hVEGF-A mAb-LgBiT, 500X

W190A 5 × 30μl

Human VEGF-A Standard

W188A 1 × 25μl

Certificado de Análisis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Condiciones de Almacenaje

AA

Patentes y Exclusiones

U.S. Pat. No. 8,809,529, European Pat. No. 2635582, Japanese Pat. No. 5889910 and other patents and patents pending.

U.S. Pat. Nos. 9,797,889, 9,797,890, 10,107,800 and 11,493,504; European Pat. No. 2970412; Japanese Pat. Nos. 7280842 and 7532562; and other patents and patents pending.

Contenido

Item Part # Presentación

Human VEGF-A Standard

W188A 1 × 25μl

Certificado de Análisis

Search by lot number

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Condiciones de Almacenaje

AA